Technology

Even before COVID-19, over 50% of pharma companies were piloting or using virtual and live remote e-detailing as standard practice. Companies need to go further to have a real impact, writes Rasim Shah.

From lightweight ERP work, to break fix services, to infrastructure- how start-up life sciences organizations, or those new to the outsourcing model, are benefiting from the use of IT partners.

Over the coming months, HCPs and manufacturers will experiment with different approaches to e-detailing, in order to arrive at an approach that works for everyone, writes Scott Morano.

Before the COVID-19 outbreak, a number of doctors were starting to use digital and connected health but many remained hesitant. Now, this has all changed.

Steve Gens and Remco Munnik offer five best-practice tips for achieving a definitive, trusted regulatory and product information asset base capable of supporting intelligent innovation.

In safety & pharmacovigilance, the requirement to capture, sift and process real-world adverse event data is vast and growing all the time. Why then, writes John Price, is the discipline lagging in its application of smart technology?

Thriving in the new COVID-19 world requires five key ingredients, which can be leveraged with a transformative approach to digital adoption in the pharma space.

Grünenthal's Florent Edouard and Veeva's Jan van den Burg talks about how the COVID-19 pandemic is changing the way the industry reaches and engages with its customers.

Developing a digital health solution that patients and HCPs will use requires creating technology that addresses unmet needs, integrates with clinical care pathways, and has strong user safeguards, writes Matt Norton.

Strategies for those chief information officers taking the digital reins at their organizations.

Dr. Jeanne Ross of the MIT Center for Information Systems Research discusses how to lead an organization’s digital transformation for the pursuit of new revenue models.

Archaic ways of working need to make way for more agile and nimble response mechanisms enabled by a systematic enterprise-wide digital upskilling strategy, writes Anand Kiran.

Anita Moser, Michael Davis, Dharmendra Sahay outline UCB's measured approach to scaling its AI capabilities.

Exploring the challenge for pharma in adapting multichannel marketing strategies for the global stage, while trying to refine messages and communicate a brand identity to multiple local audiences.

Amid concerns over a potential 'wild west' climate for data analytics in pharma, taking a long-term, proactive, and enterprise view of your company’s data may be the best way to keep your organization and reputation safe.

How to capitalize on the rise of omnichannel engagement in pharma and pursue myriad modes of message delivery in today’s digital world.

A look at the ongoing barriers and opportunities in building connections between HCPs, patients, and pharma through social media.

The key to success in a hypercompetitive marketplace is to create targeting plans that get ahead of tomorrow’s prescriptions, write Janardhan Vellore and Daniel Wetherill.

This year, data curation will become as important as document authoring and sit at the core of companies that are nimbly adjusting to an ever-changing marketplace, writes John Lawrie.

In 2020, AI will become pervasive in enterprise applications and embedded within specific commercial workflows, writes Paul Shawah.

Having invested heavily in new regulatory database systems, life sciences firms owe it to themselves to capitalize on the insights locked within those rich data assets, writes David Gwyn.

How successful commercial teams will balance the continued shift toward personalized medicine and the increased concentration on data privacy.

Chris Moore looks at how a more interconnected and dynamic healthcare ecosystem will lead to safer and better outcomes.

With public data set to play an increasingly important role in drug discovery and development, an integrated, data-driven approach to clinical planning can optimize the probability of success.

Goals for IDMP in Europe must not be diluted in 2020, if standardized medicinal product data is to be of tangible real-world benefit, says Remco Munnik.

Kellie Rademacher identifies some of the key questions to consider when choosing an AI partner.

Sandy Jennings asks: Why is the data you need never in the place you need it to be in?

Graham Francis sets out 5 critical business drivers for building a global enterprise labelling strategy over the year ahead.

How machine learning can provide an on-demand portfolio-wide view of optimal provider targeting and related field deployment.

Organizations need to be correctly set up to deploy AI and machine learning. A new approach to processes and content is often required, write Jan van den Burg and Abid Rahman.